Bio-Bridge Science, Inc. (BGES) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 36 PAGES: 28

More Info
									             Bio-Bridge Science, Inc. (BGES) - Financial and Strategic Analysis
                                          Review

       Reference Code: GDPH61621FSA                                                                                       Publication Date: SEP 2010

       1211 West 22nd Street,, Suite         Phone                                                  Revenue
                                                              +1 630 9280869                                         1 (million USD)
       615
       Oak Brook, IL                         Fax              +1 630 2036088                        Net Profit       -0.42 (million USD)
       60523                                 Website          www.bio-bridge-science.com            Employees        68
       United States                         Exchange         BGES [Over The Counter]               Industry         Pharmaceuticals & Healthcare

      Company Overview
       Bio-Bridge Science, Inc. (Bio-Bridge) is a development stage biotechnology company, engaged in the commercial development
       of biological products for the prevention and treatment of human infectious diseases, and production material in producing
       vaccines. It also provides bovine serum, which is a production material in producing vaccines. The company owns the license for
       the HIV vaccine and colon cancer vaccine technology to develop and sell it in the territories of the People's Republic of China,
       Japan, and the US. Currently, Bio-Bridge is involved in the development and commercialization of HIV-PV Vaccine I, used to
       prevent and treat infection by the human immunodeficiency virus (HIV).

      Key Executives                                                                   SWOT Analysis
                      Name                                  Title                      Bio-Bridge Science, Inc., SWOT Analysis
       Liang Qiao, M.D.                      Chairman                                  Strengths                   Weaknesses

       Wenhui Qiao                           Director
                                                                                                                          Lack of Manufacturing
                                                                                       Strategic Relationships            Experience
       Toshihiro Komoike                     Director
       Isao Arimoto                          Director
                                                                                       Expanding Market Share in          Limited Liquidity Position
       Shyh-Jing Chiang                      Director                                  Sector
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData
                                                                                       Opportunities                      Threats
      Share Data
       Bio-Bridge Science, Inc.                                                        Strategic Acquisitions             Cost Containment Pressures
                                                                                 NA
                                                                            -0.02      Emerging Markets                   Use of Hazardous Materials
       EPS (USD)
       Market Cap (million USD)                                                  0.0

       Enterprise Value (million USD)                                            0.0
                                                                                       Source: Annual Report, Company Website, Primary and Secondary
       Shares Outstanding (million)                                              35    Research
       Source: Annual Report, Company Website, Primary and Secondary Researc
								
To top